BR0015110A - Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos - Google Patents

Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos

Info

Publication number
BR0015110A
BR0015110A BR0015110-6A BR0015110A BR0015110A BR 0015110 A BR0015110 A BR 0015110A BR 0015110 A BR0015110 A BR 0015110A BR 0015110 A BR0015110 A BR 0015110A
Authority
BR
Brazil
Prior art keywords
kinesin
ksp
treating
compounds
ksp kinesin
Prior art date
Application number
BR0015110-6A
Other languages
English (en)
Inventor
Jeffrey T Finer
Gustave Bergnes
Bainian Feng
Whitney W Smith
John C Chabala
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of BR0015110A publication Critical patent/BR0015110A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"MéTODOS DE TRATAMENTO DE DOENçAS DE PROLIFERAçãO CELULAR, DE TRATAMENTO DE UM DISTúRBIO ASSOCIADO COM A ATIVIDADE DA CINESINA KSP, DE INIBIçãO DA CINESINA KSP, DE TRIAGEM DE MODULADORES DA CINESINA KPS E DE TRIAGEM DE COMPOSTOS QUE SE LIGAM NA CINESINA KSP, E, COMPOSTO". Descrevem-se quinazolinonas de fórmulas 1a, 1b, 1c e 1d Elas são úteis no tratamento de doenças de proliferação celular e de distúrbios associados com a atividade da cinesina KSP.
BR0015110-6A 1999-10-27 2000-10-26 Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos BR0015110A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19825399P 1999-10-27 1999-10-27
US21310400P 2000-06-21 2000-06-21
PCT/US2000/029585 WO2001030768A1 (en) 1999-10-27 2000-10-26 Methods and compositions utilizing quinazolinones

Publications (1)

Publication Number Publication Date
BR0015110A true BR0015110A (pt) 2002-07-02

Family

ID=26893612

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015110-6A BR0015110A (pt) 1999-10-27 2000-10-26 Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos

Country Status (19)

Country Link
EP (2) EP1686120A3 (pt)
JP (2) JP2003512461A (pt)
KR (2) KR20050049562A (pt)
CN (1) CN100381428C (pt)
AT (1) ATE327224T1 (pt)
AU (2) AU774748B2 (pt)
BR (1) BR0015110A (pt)
CA (1) CA2388646C (pt)
CZ (1) CZ20021428A3 (pt)
DE (1) DE60028227T2 (pt)
ES (1) ES2263501T3 (pt)
HK (1) HK1045994A1 (pt)
HU (1) HUP0203430A3 (pt)
IL (2) IL149164A0 (pt)
MX (1) MXPA02004162A (pt)
NO (1) NO322825B1 (pt)
NZ (2) NZ518480A (pt)
PL (1) PL203998B1 (pt)
WO (1) WO2001030768A1 (pt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2272319T3 (es) 1999-08-27 2007-05-01 Chemocentryx, Inc. Compuestos heterociclicos y metodos para modular la funcion de cxcr3.
US20070021493A1 (en) 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US8852937B2 (en) 2000-03-30 2014-10-07 Curis, Inc. Small organic molecule regulators of cell proliferation
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2002083143A1 (en) * 2000-12-11 2002-10-24 Tularik Inc. Cxcr3 antagonists
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
HUP0400264A2 (hu) 2001-06-22 2004-08-30 Pfizer Products Inc. Alacsony oldékonyságú és/vagy savra érzékeny hatóanyagokat és semlegesített savas polimereket tartalmazó gyógyszerkészítmények és eljárás az előállításukra
EP2329822A1 (en) 2001-09-05 2011-06-08 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
EP1444209A4 (en) 2001-11-07 2005-02-16 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN
WO2003043961A2 (en) * 2001-11-19 2003-05-30 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
WO2003043995A1 (en) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
AU2002363960B2 (en) * 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
CA2467726A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
ES2291543T3 (es) * 2001-12-06 2008-03-01 MERCK & CO., INC. Inhibicion de kinesina mitotica.
DE60234278D1 (de) 2001-12-06 2009-12-17 Merck & Co Inc Mitotische kinesin-hemmer
DE60231439D1 (de) * 2001-12-06 2009-04-16 Merck & Co Inc Mitotische kinesinhemmer
EP1454903B9 (en) 2001-12-11 2011-10-05 Kyowa Hakko Kirin Co., Ltd. Thiadiazoline derivatives for treating cancer
PL373412A1 (en) * 2002-05-09 2005-08-22 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods of their use for treating cellular proliferative diseases
CA2486215A1 (en) * 2002-06-14 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
DE60326248D1 (de) * 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
AU2003299612A1 (en) * 2002-12-13 2004-07-09 Cytokinetics Compounds, compositions and methods
CN1894234A (zh) * 2003-03-25 2007-01-10 武田药品工业株式会社 二肽基肽酶抑制剂
WO2004092123A2 (en) * 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
ATE537158T1 (de) 2003-04-18 2011-12-15 Kyowa Hakko Kirin Co Ltd M-stage-kinesin-inhibitor
CN1809563A (zh) 2003-06-20 2006-07-26 希龙公司 吡啶并[1,2－a]嘧啶－4－酮化合物用作抗癌药
US7666862B2 (en) * 2003-08-15 2010-02-23 Merck & Co., Inc. Mitotic Kinesin Inhibitors
US7939539B2 (en) * 2003-11-25 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Quinazolinone compounds as anticancer agents
US7439254B2 (en) * 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
US7662581B1 (en) 2003-12-18 2010-02-16 Novartis Vaccines And Diagnostics, Inc. Eg5 co-crystals
CN1898215A (zh) 2003-12-19 2007-01-17 默克公司 有丝***驱动蛋白抑制剂
JPWO2005061707A1 (ja) * 2003-12-24 2007-07-12 協和醗酵工業株式会社 癌細胞のＥｇ５阻害剤に対する感受性を判定する方法
CN1934066A (zh) * 2004-03-22 2007-03-21 默克公司 有丝***驱动蛋白抑制剂
EP1737831B1 (en) 2004-04-02 2013-05-22 Prana Biotechnology Limited Neurologically-active compounds
EP1761540B1 (en) * 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
AU2005245492A1 (en) 2004-05-21 2005-12-01 Novartis Vaccines And Diagnostics, Inc. Substituted quinoline derivatives as mitotic kinesin inhibitors
EP1755609A1 (en) * 2004-05-25 2007-02-28 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
RU2427572C2 (ru) 2004-06-18 2011-08-27 Чирон Корпорейшн N-(1-(1-бензил-4-фенил-1н-имидазол-2-ил)-2,2-диметилпропил)бензамидные производные и родственные соединения в качестве ингибиторов кинезинового белка веретена (ksp) для лечения рака
US7939538B2 (en) 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
JP2008509977A (ja) 2004-08-18 2008-04-03 アストラゼネカ アクチボラグ 癌の処置及び予防における選択された縮合複素環の鏡像異性体及びその使用
JP5635726B2 (ja) * 2004-09-14 2014-12-03 ミネルバ バイオテクノロジーズ コーポレーション 癌の診断方法及び治療方法
EP2275412A1 (en) 2004-10-19 2011-01-19 Novartis Vaccines and Diagnostics, Inc. Indole and benzimidazole derivatives
CN101107253A (zh) * 2005-01-19 2008-01-16 默克公司 有丝***驱动蛋白抑制剂
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
WO2006137490A1 (ja) 2005-06-24 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 再狭窄治療剤
TW200800951A (en) * 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
GEP20125389B (en) 2006-11-13 2012-01-25 Novartis Ag Substituted pyrazole and triazole compounds as ksp inhibitors
WO2008086122A2 (en) 2007-01-05 2008-07-17 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
GEP20115337B (en) 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
US8822497B2 (en) 2007-03-01 2014-09-02 Novartis Ag PIM kinase inhibitors and methods of their use
US8293769B2 (en) 2007-05-21 2012-10-23 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
MX2009013815A (es) 2007-06-22 2010-03-01 Arqule Inc Compuestos de quinazolinona y metodos de uso para los mismos.
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA3092449A1 (en) 2008-11-13 2010-05-20 Gilead Calistoga Llc Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2011292261B2 (en) 2010-08-17 2015-05-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US20140045832A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Insulin-Like Growth Factor-1 Receptor Inhibitors
AU2013203620B2 (en) 2012-03-05 2015-11-19 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
PT2941426T (pt) 2012-12-21 2018-07-18 Gilead Calistoga Llc Quinazolinonas aminoalquis de pirimidina substituída como inibidores de fosfatidilinositol 3-quinase
JP6207100B2 (ja) 2012-12-21 2017-10-04 ギリアード カリストガ エルエルシー イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
PL3008053T3 (pl) 2013-06-14 2018-08-31 Gilead Calistoga Llc Inhibitory 3-kinazy fosfatydyloinozytolu
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
PL3083630T3 (pl) 2013-12-20 2020-02-28 Gilead Calistoga Llc Sposoby otrzymywania inhibitorów 3-kinazy fosfatydyloinozytolu
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
EP3154958B1 (en) 2014-06-13 2020-10-07 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
NZ726360A (en) * 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
JP6383810B2 (ja) 2014-06-13 2018-08-29 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤としてのキナゾリノン誘導体
BR112016028819A2 (pt) 2014-06-13 2017-08-22 Gilead Sciences Inc composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
CN111189935A (zh) * 2019-12-30 2020-05-22 卓和药业集团有限公司 盐酸右美托咪定的高效液相色谱分析方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
ATE303997T1 (de) * 1997-06-09 2005-09-15 Pfizer Prod Inc Chinazolin-4-on ampa antagonisten
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones

Also Published As

Publication number Publication date
KR20050049562A (ko) 2005-05-25
JP2003512461A (ja) 2003-04-02
NZ530074A (en) 2005-03-24
NZ518480A (en) 2004-02-27
EP1226129A1 (en) 2002-07-31
DE60028227T2 (de) 2007-03-29
CN1413198A (zh) 2003-04-23
NO20021907D0 (no) 2002-04-23
AU774748B2 (en) 2004-07-08
JP4116332B2 (ja) 2008-07-09
EP1686120A3 (en) 2007-05-30
HK1045994A1 (en) 2002-12-20
KR20020062930A (ko) 2002-07-31
AU1439801A (en) 2001-05-08
PL354891A1 (en) 2004-03-22
AU2004218601A1 (en) 2004-10-28
NO20021907L (no) 2002-06-07
CA2388646C (en) 2009-01-27
EP1686120A2 (en) 2006-08-02
CA2388646A1 (en) 2001-05-03
HUP0203430A3 (en) 2003-07-28
HUP0203430A2 (en) 2003-05-28
CZ20021428A3 (cs) 2002-11-13
CN100381428C (zh) 2008-04-16
WO2001030768A9 (en) 2002-08-15
PL203998B1 (pl) 2009-11-30
JP2003048881A (ja) 2003-02-21
ES2263501T3 (es) 2006-12-16
MXPA02004162A (es) 2003-08-20
WO2001030768A1 (en) 2001-05-03
NO322825B1 (no) 2006-12-11
IL149164A (en) 2007-05-15
EP1226129B1 (en) 2006-05-24
DE60028227D1 (de) 2006-06-29
IL149164A0 (en) 2002-11-10
ATE327224T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
BR0015110A (pt) Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
BR0111898A (pt) Métodos de tratamento de doenças de proliferação celular, e de um distúrbio associado com a atividade de cinesina ksp, método de inibição da cinesina ksp, composto, método de triagem de moduladores da cinesina kps, e, método de triagem de compostos que se ligam à cinesina ksp
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
SE9900100D0 (sv) New compounds
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
GEP20032897B (en) Epothilone Derivatives
DE69429524T2 (de) Aminocyclohexylester und ihre anwendung
AU7031500A (en) Therapeutic quinazoline compounds
WO2000071493A3 (en) INHIBITORS OF FACTOR Xa
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
DE50014532D1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
BR0315247A (pt) Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
AU9157698A (en) Piperazine derivatives active on the lower urinary tract
BR0115882A (pt) Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
NO20006699D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
BR9901387A (pt) Composições para a cura de polìmero.
NO20012169L (no) Forbindelser med veksthormonfrigjörende egenskaper
UA36531A (uk) Спосіб вибору тактики лікування гострої непрохідності тонкої кишки злукового походження
RU98109220A (ru) Способ лечения экземы

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 239/91, A61K 31/517, A61K 37/02

Ipc: C07D 239/91 (2009.01), A61K 31/517 (2009.01), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (VIII), 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.